(NASDAQ: OCS) Oculis Holding Ag's forecast annual revenue growth rate of 271.79% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Oculis Holding Ag's revenue in 2025 is $913,414.On average, 4 Wall Street analysts forecast OCS's revenue for 2025 to be $45,392,929, with the lowest OCS revenue forecast at $20,001,780, and the highest OCS revenue forecast at $60,560,945. On average, 4 Wall Street analysts forecast OCS's revenue for 2026 to be $1,067,428,326, with the lowest OCS revenue forecast at $40,003,560, and the highest OCS revenue forecast at $2,787,470,285.
In 2027, OCS is forecast to generate $2,815,528,338 in revenue, with the lowest revenue forecast at $2,633,012,095 and the highest revenue forecast at $2,998,044,580.